Review article · 2024
Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials
Seminars in Arthritis and Rheumatism, 69, 152563 · Published 1 October 2024 · DOI 10.1016/j.semarthrit.2024.152563
In brief
“Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials” is a 2024 review article by Alisson Pugliesi and 8 co-authors, published in Seminars in Arthritis and Rheumatism. OpenAlex counts 15 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 15
- Most cited in
- 2025 (7)
- Field-weighted impact
- 0.90
- References
- 47
- Authors
- 9
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Pugliesi, A., Oliveira, D., Filho, V. A. D. S., Machado, J. D. O., Pereira, A. G., Bichuette, J. D. C. S., Sachetto, Z., de Carvalho, L. S. F., & Bértolo, M. B. (2024). Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials. Seminars in Arthritis and Rheumatism, 69, 152563. https://doi.org/10.1016/j.semarthrit.2024.152563
MLA 9
Pugliesi, Alisson, et al. “Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.” Seminars in Arthritis and Rheumatism, vol. 69, 2024, p. 152563. https://doi.org/10.1016/j.semarthrit.2024.152563.
Chicago
Pugliesi, Alisson, Daniela Oliveira, Vani Abreu de Souza Filho, Júlia de Oliveira Machado, Aline Gonçalves Pereira, Júlia de Castro Silveira Bichuette, Zoraida Sachetto, Luiz Sérgio Fernandes de Carvalho, and Manoel Barros Bértolo. 2024. “Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.” Seminars in Arthritis and Rheumatism 69: 152563. https://doi.org/10.1016/j.semarthrit.2024.152563.
Harvard
Pugliesi, A. et al. (2024) ‘Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials’, Seminars in Arthritis and Rheumatism, 69, p. 152563. doi:10.1016/j.semarthrit.2024.152563.
IEEE
A. Pugliesi et al., “Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials,” Seminars in Arthritis and Rheumatism, vol. 69, p. 152563, 2024, doi: 10.1016/j.semarthrit.2024.152563.
BibTeX
@article{pugliesi2024cardiovascular,
title = {{Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials}},
author = {Pugliesi, Alisson and Oliveira, Daniela and Filho, Vani Abreu de Souza and Machado, Júlia de Oliveira and Pereira, Aline Gonçalves and Bichuette, Júlia de Castro Silveira and Sachetto, Zoraida and de Carvalho, Luiz Sérgio Fernandes and Bértolo, Manoel Barros},
journal = {Seminars in Arthritis and Rheumatism},
year = {2024},
volume = {69},
pages = {152563},
doi = {10.1016/j.semarthrit.2024.152563},
url = {https://doi.org/10.1016/j.semarthrit.2024.152563}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 7 | |
| 2026 | 7 |
Its field-weighted citation impact is 0.90: it has been cited 0.90 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- JAK inhibitors
- tocilizumab
- TNF-alpha inhibitors
- rheumatoid arthritis
- major adverse cardiovascular events
- all-cause mortality
- cardiovascular safety
- drug comparison
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Pugliesi, A., Oliveira, D., Filho, V. A. D. S., Machado, J. D. O., Pereira, A. G., Bichuette, J. D. C. S., Sachetto, Z., de Carvalho, L. S. F., & Bértolo, M. B. (2024). Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials. Seminars in Arthritis and Rheumatism, 69, 152563. https://doi.org/10.1016/j.semarthrit.2024.152563
How many times has this paper been cited?
15 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Alisson Pugliesi, Daniela Oliveira, Vani Abreu de Souza Filho, Júlia de Oliveira Machado, Aline Gonçalves Pereira, Júlia de Castro Silveira Bichuette, Zoraida Sachetto, Luiz Sérgio Fernandes de Carvalho, Manoel Barros Bértolo.
What is the DOI of this paper?
10.1016/j.semarthrit.2024.152563, permanently at https://doi.org/10.1016/j.semarthrit.2024.152563. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.